Hookipa Pharma files for US-$86m IPOUS-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO. more ➔
New approach to treat eye cancerA research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer. more ➔
Pfizer buys stake in liver gene therapy pl...Pfizer Inc has paid €45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801. more ➔
Sotio on track for 2nd Phase III trialAfter positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate … more ➔
AMR Conference in Berlin: Call for better...More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). more ➔
Biomarker can exclude acute kidney injuryData presented at the 24th AKI & CRRT conference, suggest that the kidney function marker pro-enkephalin (penKid) is capable to rule out acute kidney injury (AKI) with a single measurement. more ➔
Researchers target neuroblastoma with ALK-...Researchers at Celldex Therapeutics, Inc and Nerviano Medical Science Srl report elimination of the most common childhood cancer by an ADC in xenografted mice expressing either wild-type or mutated … more ➔
AMR: Germany set to invest €39m into CAR...Global antibacterial innovation network CARB-X announced during an AMR business conference in Berlin that Germany has joined the CARB-X partnership. more ➔
AstraZeneca partners with Seres Therapeuti...Under a three-year agreement, British pharma giant AstraZeneca plc pays €20m and R&D costs to Seres Therapeutics Inc, which will identify patterns in the microbiome predicting therapy response … more ➔
AMR: Snipr Biome Aps raises €43m to prog...Copenhagen-based SNIPR BIOME Aps raised €43m in a series A financing led by seed investor Lundbeckfonden Emerge (Copenhagen) and LSP and co-financed by North-East Family Office (Copenhagen) … more ➔
